SAB Biotherapeutics, Inc. (SABS)

In Q3 2025, SAB Biotherapeutics reported an EPS of -$0.21, surpassing estimates, and had a cash position of $161.5 million, expected to last through 2028. The company initiated its Phase 2b SAFEGUARD trial for SAB-142 and presented positive Phase 1 data. SAB Biotherapeutics participated in several investor and industry conferences and appointed a new Board Chair and independent Director. The company's president received a grant of 3,000,000 stock options. The share price increased by 103% between January 30, 2025, and January 29, 2026, but experienced a decline following a sell signal on February 3, 2026.

SAB Biotherapeutics' demand is driven by clinical trial progress, regulatory milestones, and market adoption rather than traditional seasonality. Revenue is tied to research and development activities and potential commercialization. Historically, October has shown the highest probability of positive stock returns, while February has shown the lowest.

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies using fully human polyclonal antibodies. The company operates in the Healthcare sector, specifically the Biotechnology/Biopharmaceutical industry, and utilizes its DiversitAb™ platform to produce high-potency human immunoglobulin G (hIgG) antibodies. Key product candidates include SAB-142, in Phase 2b clinical trials for Type 1 Diabetes (T1D), SAB-185, a fully-human polyclonal antibody therapeutic candidate that was in Phase III clinical trials for the treatment of COVID-19 and SAB-176, in development for severe influenza.

SAB Biotherapeutics, Inc. is headquartered in Sioux Falls, South Dakota, with an office in Miami Beach, Florida. Its clinical trials, including the Phase 2b SAFEGUARD trial for SAB-142, are conducted across the United States, Australia, and New Zealand.

SAB Biotherapeutics has a positive brand reputation, with a consensus "Strong Buy" rating from analysts. The company's innovative DiversitAb platform, promising product pipeline, and strong stock performance contribute to its reputation. No significant negative events impacting the company's reputation were identified.

SAB Biotherapeutics, Inc. has significant institutional ownership, with 41 institutional owners holding 29,500,387 shares, representing 61.97% or 18.66% of the company. Insider ownership is reported at 14.29% or 25.06%. Major institutional owners include Vivo Capital, LLC, RA Capital Management, L.P., and Vanguard Group Inc.